Eric Sachetta Buys 34,697 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 34,697 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were purchased at an average price of $3.25 per share, with a total value of $112,765.25. Following the completion of the transaction, the director owned 209,310 shares of the company’s stock, valued at $680,257.50. This trade represents a 19.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sensus Healthcare Stock Down 2.1%

SRTS stock opened at $3.29 on Thursday. The firm has a market cap of $54.16 million, a price-to-earnings ratio of -3.50 and a beta of 1.10. Sensus Healthcare, Inc. has a 12-month low of $2.66 and a 12-month high of $5.49. The company’s fifty day simple moving average is $3.03 and its 200 day simple moving average is $3.54.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of SRTS. Rothschild Wealth LLC purchased a new position in Sensus Healthcare during the fourth quarter worth about $500,000. Greenline Wealth Management LLC purchased a new stake in Sensus Healthcare in the 4th quarter valued at about $513,000. Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $219,000. State Street Corp lifted its position in shares of Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Sensus Healthcare in the 4th quarter worth approximately $79,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SRTS has been the topic of a number of research analyst reports. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Lake Street Capital reduced their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.